Opus Genetics Announces Financial Results for Second Quarter 2025 and Provides Corporate Update

- Positive 12-month Phase 1/2 clinical data in adult cohort and early pediatric clinical data support potential for meaningful vision restoration with OPGx-LCA5 -

- FDA grants Regenerative Medicine Advanced Therapy (RMAT) designation for OPGx-LCA5 -

Read more at globenewswire.com